Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
Pharmaceutical pipeline: there are no Phase 1 through Phase 3 trials of 5-Amino-1MQ itself registered on ClinicalTrials.gov as of June 2026
[9] With the standard regimen, we do not expect any liver issues or nerve issues
By inhibiting NNMT and preserving NAD, 5-Amino-1MQ indirectly boosts SIRT1 activity , leading to: Increased fat oxidation SIRT1 activates PGC-1 (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), a master regulator of mitochondrial biogenesis and fat metabolism
This is something that you are your doctor will decide before you begin receiving treatments
5-Amino-1MQ Key Research Facts Chemical name: 5-Amino-1-Methylquinolinium (also abbreviated as 5A-1MQ or 5MQ) Target enzyme: Nicotinamide N-Methyltransferase (NNMT) Mechanism: Competitive inhibition of NNMT reduces 1-MNA production, preserves nicotinamide for NAD+ synthesis and SAM for epigenetic methylation Selectivity: High selectivity for NNMT does not inhibit related SAM-dependent methyltransferases or NAD+ salvage pathway enzymes Membrane permeability: High passive and active transport permeability confirmed in PAMPA and Caco-2 cell assays NNMT expression: Upregulated in obese adipose tissue, multiple cancer types, and aged skeletal muscle tissue contexts of primary research interest Downstream targets: NAD+ availability, SIRT1/SIRT3 activity, SAM-dependent epigenetic methylation, lipogenesis, energy expenditure Pre-clinical models: Diet-induced obese (DIO) mice, 3T3-L1 adipocyte cell models, aged mouse skeletal muscle models, HeLa cancer cell lines In vitro cell viability: No impact on cell viability at 10 M concentration in 3T3-L1 pre-adipocytes in published toxicity profiling What Does 5-Amino-1MQ Do in Research
